BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2737629
Number of visits today
625
Number of downloads
2008993
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Wang Q, Ying Q, Zhang X, Ye T, Chen K, Li G. A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells. Marine Drugs 2023;21:77. [DOI: 10.3390/md21020077] [Reference Citation Analysis]
2 Cousin S, Toulmonde M, Kind M, Guegan JP, Bessede A, Cantarel C, Bellera C, Italiano A. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp Hematol Oncol 2022;11:104. [PMID: 36474303 DOI: 10.1186/s40164-022-00338-2] [Reference Citation Analysis]
3 Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep 2022;24:1801-19. [PMID: 36255603 DOI: 10.1007/s11912-022-01339-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2022;12:919072. [DOI: 10.3389/fonc.2022.919072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345